1 **Cardiopulmonary Exercise Testing in a Prospective Multicenter Cohort of Older Adults:** 2 The Study of Muscle, Mobility and Aging (SOMMA) 3 Cody Wolf, MS^{1*}; Terri L. Blackwell, MA^{2*}; Eileen Johnson, MPH²; Nancy W. Glynn, PhD³; 4 Barbara Nicklas, PhD⁴; Stephen B. Kritchevsky, PhD⁴; Elvis A. Carnero, PhD⁵; Peggy M. 5 Cawthon, PhD, MPH^{2,6}; Steven R. Cummings, MD^{2,6}; Frederico G. S. Toledo, MD⁷; Anne B. 6 Newman, MD, MPH³; Daniel E. Forman, MD^{8*}; Bret H. Goodpaster, PhD^{5*} 7 8 9 ¹Department of Health and Physical Activity, University of Pittsburgh, Pittsburgh, Pennsylvania, 10 USA. ²San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San 11 12 Francisco, California, USA. 13 ³Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁴Department of Internal Medicine-Gerontology and Geriatric Medicine, Wake Forest University 14 15 School of Medicine, Winston-Salem, North Carolina, USA. 16 ⁵Translational Research Institute, AdventHealth, Orlando, FL, USA. 17 ⁶Department of Epidemiology and Biostatistics, University of California, San Francisco, 18 California, San Francisco, California, USA. ⁷Department of Medicine-Division of Endocrinology and Metabolism, University of Pittsburgh 19 20 School of Medicine, Pittsburgh, Pennsylvania, USA.

- 21 ⁸Department of Medicine (Geriatrics and Cardiology) University of Pittsburgh; Geriatrics
- 22 Research, Education and Clinical Care (GRECC), VA Pittsburgh Healthcare System, Pittsburgh,
- 23 PA
- 24 *These authors contributed equally
- 25 Corresponding authors:
- 26 Bret H. Goodpaster, PhD
- 27 Translational Research Institute
- 28 301 East Princeton Street
- 29 Orlando, FL 32804email: bret.goodpaster@adventhealth.com
- 30
- 31 Short Title: Cardiopulmonary Exercise Testing in Older Adults
- 32 Keywords: cardiorespiratory fitness, aging, frailty, muscle, VO2peak
- 33 Abstract word count: 350
- 34 Main text word count: 4965
- 35 Number of Figures: 4
- 36 Number of Tables: 4
- 37 Number of References: 40

38 ABSTRACT

39 **BACKGROUND:** Cardiorespiratory fitness (CRF) measured by peak oxygen consumption 40 (VO₂peak) declines with aging and correlates with mortality and morbidity. Cardiopulmonary 41 Exercise Testing (CPET) has long been the criterion method to assess CRF, but its feasibility, 42 efficacy and reliability in older adults is unclear. The large, multicenter Study of Muscle, 43 Mobility and Aging (SOMMA) employed CPET to evaluate the mechanisms underlying declines 44 in mobility with aging among community-dwelling older adults. Our primary objective was to 45 design and implement a CPET protocol in older adults that was dependable, safe, scientifically 46 valuable, and methodologically reliable. 47 **METHODS:** CPET was performed using treadmill exercise in 875 adults \geq 70 years. A 48 composite protocol included a symptom-limited peak exercise phase and two submaximal phases 49 to assess cardiopulmonary ventilatory indices during 1) participants' preferred walking speed 50 and 2) at slow walking speed of 1.5 mph (0.67 m/s). An adjudication process was in place to 51 review tests for validity if they met any prespecified criteria (VO₂peak <12.0 ml/kg/min; 52 maximum heart rate (HR) <100 bpm; respiratory exchange ratio (RER) <1.05 and a rating of 53 perceived exertion <15). A repeat test was performed in a subset (N=30) to assess 54 reproducibility. 55 **RESULTS:** CPET was safe and well tolerated, with 95.8% of participants able to complete the 56 VO₂peak phase of the protocol. Only 56 (6.4%) participants had a risk alert during any phase of 57 testing and only two adverse events occurred during the peak phase: a fall and atrial fibrillation. 58 The average \pm standard deviation for VO₂peak was 20.2 \pm 4.8 mL/kg/min, peak HR 142 \pm 18 59 bpm, and peak RER 1.14 ± 0.09 . VO₂peak and RER were slightly higher in men than women. 60 Adjudication was indicated in 47 participants; 20 were evaluated as valid, 27 as invalid (18 had a

- 61 data collection error, 9 did not reach VO2peak). Reproducibility of VO2peak was high (intraclass
- 62 correlation coefficient=0.97).
- 63 **CONCLUSIONS:** CPET was feasible, effective and safe for community-dwelling older adults,
- 64 many of whom had multimorbidity and frailty. These data support a broader implementation of
- 65 CPET to provide important insight into the role of CRF and its underlying determinants in aging
- 66 and age-related conditions and diseases.

68 Clinical Perspective

69

70 What Is New?

- Performing cardiopulmonary exercise testing in a community dwelling older adult with
- 72 multimorbidities or frailty is feasible and exceptionally safe under highly trained exercise
- 73 physiologists and physician supervision.
- Reproducibility of VO₂peak among community-dwelling older adults with significant
- 75 clinical complexity was high (intraclass correlation coefficient=0.97).
- The VO₂peak observed was comparable to established normative data for older adults,
- and adds merit to the limited data collected on VO₂peak norms in older adults.
- 78 What Are the Clinical Implications?

• Ventilatory gas collection during clinical cardiac stress testing may be valuable to plan of

- 80 care in routine management of older adults due to the important role of aerobic fitness on
- 81 morbidity and mortality.
- Cardiopulmonary exercise testing can provide insight into the role of cardiorespiratory
- 83 fitness and its underlying determinants in aging and age-related conditions and diseases.

85 Non-standard Abbreviations and Acronyms

ACSM	American College of Sports Medicine
APMHR	Age-Predicted Maximal Heart Rate
BMI	body mass index
BP	blood pressure
CES-D	Center for Epidemiological Studies-Depression
CHAMPS	Community Healthy Activities Model Program for Seniors
CI	confidence interval
CPET	cardiopulmonary exercise testing
CRF	cardiorespiratory fitness
CV	coefficient of variation
ECG	Electrocardiogram
EC_W	energetic cost of walking
HR	heart rate
ICC	intraclass correlation coefficient
MET	metabolic equivalent of task
MR	magnetic resonance
PWS	preferred walking speed
RER	respiratory exchange ratio
RPE	rating of perceived exertion
SD	standard deviation
SOMMA	Study of Muscle, Mobility and Aging
SWS	slow walking speed

VCO₂ carbon dioxide exhalation

- VE minute ventilation
- VO₂ oxygen inhalation
- VO₂peak peak oxygen consumption

87 INTRODUCTION

88 Cardiorespiratory fitness (CRF) refers to the capacity of the circulatory and respiratory systems to supply oxygen to skeletal muscle mitochondria for energy production needed during 89 90 physical activity.¹ Peak oxygen consumption (VO₂peak) is the criterion measure of CRF, which 91 declines with aging, is a key metric of physical function and a strong predictor of risk for morbidity and mortality.² It is often applied to diagnose and evaluate the effects of disease as 92 well as constitutive physiologic mechanisms.³ VO₂peak assessed using symptom-limited 93 cardiopulmonary exercise testing (CPET) is a vetted criterion metric of CRF.^{1,4,5} CPET entails an 94 95 exercise provocation to stimulate integrated physiologic responses (cardiac, pulmonary, muscle, 96 autonomic, circulatory) that can be assessed through patterns in ventilatory indices.^{1,6} 97 Measurements of oxygen consumption (VO₂), carbon dioxide production (VCO₂), minute 98 ventilation, and associated indices during progressive exercise intensity assess aerobic capacity, 99 ventilatory efficiency, and other aspects of physical function. These can discern patterns of 100 performance and physical limitation, with a wide range of clinical and research applications. The 101 reliability of CPET for measuring CRF in younger populations has been well-established.^{1,7} Its 102 application, feasibility and reliability in older adults, however, is less certain. Studies to validate 103 VO₂peak in older adults have been limited to small sample sizes, with many lingering questions 104 regarding their feasibility, reliability and safety amidst age-related issues of mobility impairments, multimorbidity, frailty, fear of falling or maximal exertion.^{8,9} 105 106 The conceptual value of CRF assessments using CPET in older adults is strong. VO₂peak correlates with physical function^{10–12}, frailty, disability, and mortality¹³ in older adults. CPET has 107 been useful in determining the etiology of dyspnea, a common problem for older adults.¹ 108

Likewise, CPET is useful in determining diagnosis, prognosis and management of heart failure,
chronic obstructive lung disease and other clinical challenges pertinent to older adults.¹

In the Study of Muscle, Mobility and Aging (SOMMA), a study designed to distinguish subcellular mechanisms in skeletal muscle underlying mobility disability and functional decline over a three year period in older adults, CPET is integral to the primary study objectives to clarify key relationships between skeletal muscle mitochondrial respiration and CRF. Optimal accuracy of CPET is paramount to better understand these relationships.¹⁴ SOMMA and other studies of aging and age-related conditions and diseases require a CPET protocol that is dependable, safe and reliable.

118 Many rudimentary issues for exercise testing become more complex for older adults, 119 especially those who have no prior experience with exercise testing or training. Goals to achieve 120 adequate motivation and confidence for a high exercise workload are often difficult, especially as 121 many older adults become fearful at higher exercise intensities. While CPET using a bicycle has 122 advantages of stability and safety, cycling is not an exercise that is familiar to many older 123 Americans. In comparison, walking is a more familiar exercise that may provide a more 124 meaningful evaluation of physiologic capacities, but concerns regarding walking limitations (gait 125 instability, pain) and safety (falls, anxiety, hemodynamics, arrhythmia) may also increase with treadmill modes.^{15–17} Similarly, while breathing through a mouthpiece is commonly employed 126 127 for CPET, the discomfort associated with mouthpieces may become disproportionate due to 128 changes in jaw strength and dentition, and difficulty tolerating a nose clip and breathing 129 exclusively through the mouth. For many older adults, face masks provide greater comfort and 130 feasibility during exercise. However, it is not clear if face masks can achieve effective air seals

for accurate ventilatory measurements for those experiencing age-related changes in facial
 structure.¹⁸

The primary aim of this report was to provide a detailed overview of the SOMMA CPET protocol. We report methods to achieve dependable assessments of cardiorespiratory fitness (VO₂peak) and submaximal exercise performance with associated safety and reliability. We also examine feasibility of CPET among subpopulations in SOMMA with functional limitations and comorbidities.

138

139 METHODS

140 SOMMA Participants

141 Details of the design of SOMMA are published elsewhere (https://sommaonline.ucsf.edu).¹⁹ 142 Volunteers were recruited at two clinical sites (University of Pittsburgh and Wake Forest University School of Medicine) from April 2019 to December 2021.¹⁹ Individuals were eligible 143 144 to participate if they were \geq 70 years old, willing and able to complete a skeletal muscle biopsy 145 and undergo magnetic resonance (MR). Individuals were excluded if they reported an inability to 146 walk $\frac{1}{4}$ mile or climb a flight of stairs; had body mass index (BMI) ≥ 40 kg/m²; had an active 147 malignancy or dementia; had medical contraindication to biopsy or MR. Finally, participants 148 must have been able to complete the 400-meter walk; those who seemed unable to do so at the 149 screening visit completed a 4-meter walk to ensure their walking speed was ≥ 0.6 m/s. All 150 participants provided written informed consent, and the study was approved by the WIRB-151 Copernicus Group. The goal was to collect CPET data on all participants at the baseline visit. 152 The SOMMA baseline data was collected over three separate visits, with a goal of completion

within 30 days. The first visit included a 400-meter walk test, strength and physical function
measures, a detailed medical review of medical history and a resting electrocardiogram (ECG).
CPET was done at the second visit. This provided the CPET team several days to obtain any
pertinent details of prior ECGs or medical history to ensure each participant's safety to complete
the anticipated CPET. Completion of the 400-meter walking test provided SOMMA participants
with an initial experience of a monitored functional assessment that contributed to greater
confidence for the later CPET.

160

161 Rationale for CPET Protocol Selection

162 The CPET protocol was developed by a working group of exercise physiologists and 163 investigators with expertise in studies of older adults. CPET in SOMMA was performed using 164 treadmill exercise with the rationale that walking is a more universally familiar exercise to older 165 adults than bicycling. Walking was also better aligned with functional capacities needed for 166 independent mobility. The SOMMA CPET protocol was structured with 3 phases to capture a 167 full range of functional domains: (Phase 1) preferred walking speed (PWS); (Phase 2) 168 progressive exercise with increasing incline to evaluate VO₂peak (Peak); (Phase 3) slow walking 169 speed (SWS). The reasoning for a three-phase protocol was to observe peak aerobic capacity and 170 incorporate other novel submaximal indices of walking energetics.¹⁰ 171 CPET was conducted by experienced exercise physiologists under the supervision of a 172 physician or physician assistant. Staff conducting CPET went through formal, centralized 173 training with steps to standardize the testing process, including participant encouragement.

174 Contraindications for exercise testing were consistent with standard American College of Sports

175	Medicine (ACSM) guidelines. ²⁰ To further optimize safety, eligibility screening included an
176	"alert system", where potential safety concerns were systematically reviewed. These potential
177	concerns, grouped as low and high risk, included identification of alerts from blood pressure
178	(BP), heart rate (HR), and ECG that warranted further evaluation before CPET testing or, if
179	occurring during CPET, stopping testing and evaluating clinically (Listed in Table 1). Pre-CPET
180	low-risk alerts required clearance by the study physician for CPET to proceed or were not
181	cleared for Phase 2, while high-risk alerts led to a hold until participants were cleared by their
182	personal physician, the study physician and the study medical safety officer. Alerts during CPET
183	were consistent with the ACSM guideline's relative and absolute contraindications for stopping
184	the test. ²⁰

185

186 **CPET Equipment**

187 Exercise was performed on a treadmill (Trackmaster, Full Vision Inc. Newton, KS) coupled 188 with a cardiopulmonary metabolic cart (Medgraphics Ultima Series, Medgraphics Corporation, 189 St. Paul, MN). Breath-by-breath ventilatory measurements were assessed using face masks (Hans 190 Rudolph Inc., Shawnee, KS) fitted to each participant according to size options. Initially, an 191 adjustable neoprene face mask that was designed to stretch over participants' faces was used 192 (Medgraphics, n=94). After discovering inconsistencies in ventilatory measurements from the 193 neoprene mask, its use was discontinued and the Hans Rudolph mask was used. If a participant 194 preferred, a mouthpiece and nose clip were substituted for the face mask (n=3 participants).

12-lead (Mason-Likar) ECG waveforms and pulse oxygen saturation (Nonin Inc., Plymouth,
 MN) were monitored continuously. HR, BP and rating of perceived exertion (RPE)²¹ were
 assessed in each of three phases of the CPET protocol.

198

199 Familiarization

200 A familiarization period was performed prior to starting the CPET protocol. The goal of 201 familiarization was to first demonstrate and then ensure the participant could achieve proper 202 walking gait, and then explain each phase of the protocol. Exercise physiologists demonstrated 203 these steps before encouraging the participants to repeat them and confirm successful learning. 204 Familiarization included emphasis on the importance of normal stride length, safe positioning, 205 regular breathing, and focusing eyes ahead. The speeds utilized at each phase were demonstrated, 206 differentiating between PWS and SWS. Following the familiarization period, the participant was 207 prepared with electrode lead placement and face mask fitting. Participants then sat for resting 208 hemodynamics.

209

210 The CPET Protocol

211 The CPET protocol was structured with three phases: (Phase 1) preferred walking speed

212 (PWS); (Phase 2) progressive exercise with increasing incline to evaluate VO₂peak (Peak);

213 (Phase 3) slow walking speed (SWS). Phases 1 and 2 were conducted sequentially without

214 interruption. After Phase 2, participants were given a 20-minute rest before beginning Phase 3.

Phase 1 consisted of 5 minutes of treadmill walking at each participant's PWS with 0%
incline. The PWS was based on the participant's gait speed during the 400-meter walk test that
was completed at the first SOMMA study visit. Continuous collection of ventilatory gases was
performed as participants walked, along with assessments of RPE and manual BP at minutes 4
and 5.

The exercise physiologists used consistent coaching phrases to describe Phase 1 as a "warmup" before the progressive intensity exercise of Phase 2 began. However, if a participant reached a peak effort during Phase 1 (n=4), exercise intensity would not increase, and CPET would progress directly to recovery part of Phase 2.

224 Phase 2 entailed a progression of exercise intensity to achieve VO₂peak. The goals were to 225 achieve a respiratory exchange ratio (RER) \geq 1.05 and/or RPE \geq 17. The VO₂peak is defined as 226 the highest 30-second average of VO₂ achieved during Phase 2. The Peak protocol was premised 227 on a Modified Balke protocol¹⁷ with systematized modifications to better suit the SOMMA 228 population.

229 Whereas the Modified Balke protocol usually entails walking at either 2.0 or 3.0 mph (0.89 230 or 1.34 m/s), in SOMMA the initial treadmill speed was the PWS. If a participant's PWS was 231 <2.0 mph (0.89 m/s), the initial speed used in Phase 2 was increased, but with discretion by the 232 exercise physiologist to select a speed that was well tolerated; the initial speeds used in Phase 2 233 were <2.0 mph (0.89 m/s) for 49 participants. Furthermore, the Modified Balke protocol usually 234 starts at a 2.5% incline and increases 2.5% at each 2-minute stage thereafter until a participant 235 reaches volitional fatigue. In SOMMA, 2.5% increases in treadmill incline were made every 2 236 minutes, but limited to a maximal incline of 10% to avoid biomechanically awkward walking at steeper angles. Thereafter, higher exercise intensity beyond the 10% incline relied on increasing 237

238 treadmill speed up to 0.5 mph (0.22 m/s) at each 2-minute stage until volitional fatigue. To evoke 239 a maximal effort, participants were prompted before each change in speed and incline and 240 encouraged to continue until they could no longer maintain the given workload. Every 2 minutes 241 and at peak performance, HR, BP and RPE were assessed. 242 Once the participant reached volitional fatigue, a 1-minute recovery period walking at 1 mph 243 (0.45 m/s) and 0% incline was initiated, followed by 4 minutes of seated recovery. During the 244 recovery periods continuous assessments of ventilatory indices, ECG, HR, and oxygen saturation 245 were completed as well as monitoring of BP and RPE at minute 5. The participant was asked to 246 continue sitting for the remainder of the 20-minute recovery period. 247 During Phase 3, the participant walked on the treadmill at 1.5 mph (0.67 m/s) and 0% incline, 248 with continuous collection of ventilatory gases and assessments of RPE at minutes 4 and 5 and 249 manual BP at minute 5. 250 Throughout each of the phases of testing, risk alerts associated with the exercise provocation 251 were carefully monitored and addressed by the supervising exercise physiologist and clinician as 252 per ACSM guidelines.²⁰

253

254 Quality Control

The CPET metabolic cart received maintenance every 6 months to ensure proper calibration (ventilatory, treadmill speed, grade). The CPET working group optimized the protocol and face mask used for testing, created a format for saving and sharing data, and created an adjudication process to review validity of tests in question. The CPET working group met regularly to review

259	protocol questions, safety and data quality. Data collected were reviewed monthly by the
260	working group to evaluate consistency between sites in the application of the protocol.
261	

262 Adjudication of VO2peak Data

To ensure that Phase 2 data were accurate, tests were adjudicated if they met at least one of the following criteria: VO₂peak <12 ml/kg/min; maximum RPE <15 and maximum RER<1.05 (up to the start of recovery); maximum HR <100 bpm. Adjudicators were assigned from the CPET working group and were provided with data from CPET along with participant characteristics (age, sex, anthropometrics, gait speed, medication use). Adjudicators determined the validity of the Phase 2 data, as well as indicated if the data had a systematic problem and should not be used for the other two phases.

270

271 *Repeatability*

272 Repeatability testing was conducted on a convenience sample of n=30 (15 per site, equal
273 number by sex), who repeated all phases of the CPET protocol. The goal was for the repeat tests
274 to be completed 7 days after the initial CPET, at the same time of day.

275

276 Assessment of Walking Energetics

277 To examine walking energetics for both Phases 1 and 3 (PWS, SWS), the energetic cost of

278 walking (EC_W) was calculated as the average VO₂ consumption from the last 3 minutes of each

test. We derived the energy cost-capacity ratio of both phases as 100*EC_W/VO₂peak.¹¹

280

281 Participant Phenotypes and Characteristic Data

282	SOMMA recruited community-dwelling older adults with diverse characteristics.
283	Multimorbidity, frailty and recurrent falling were quantified as it is often assumed that these
284	subpopulations are unable to complete maximal exercise testing. Depression was defined as a
285	score ≥ 10 on the Center for Epidemiological Studies Depression Scale (CES-D-10). ²²
286	Information on self-reported history of chronic health conditions and depression was combined
287	to create the SOMMA multimorbidity index (0-11). ²³ The frailty phenotype was defined
288	following the criteria by Fried et al. ²⁴ Participants reported information about lifestyle, falls
289	history, mobility limitations, smoking status and medication use. ^{25,26} Participants were
290	categorized as recurrent fallers if they reported ≥ 2 falls in the past year. Self-reported physical
291	activity was assessed with the Community Healthy Activities Model Program for Seniors
292	(CHAMPS) questionnaire. ²⁷ Age predicted maximal heart rate (APMHR) was estimated as 208
293	0.7 *age. ²⁸ Slow gait speed was defined as ≤ 0.8 m/s on the 4-meter test. Obesity was defined as
294	BMI>30 kg/m ² .

295

296 Statistical Analysis

297 Participant characteristics, phenotypic data and CPET phase completion were summarized by 298 means and standard deviations (SD) for continuous variables, counts and percentages for 299 categorical variables. Differences in these characteristics between participants cleared or 300 excluded from the Phase 2 portion of CPET were analyzed using t-tests or Wilcoxon rank-sum 301 tests for continuous variables, χ^2 tests for categorical characteristics. Similar comparisons were

302	performed by phenotype and mask type. Similarly, differences in CPET measures by sex was
303	analyzed. The distribution of VO ₂ peak across age was displayed graphically.
304	For the repeatability analysis, differences between CPET parameters from the original and
305	repeat measures were examined using paired t-tests. Agreement between the two measures was
306	examined with correlations and intraclass correlation coefficients (ICC) and 95% confidence
307	intervals (CI), computed using a 2-way analysis of variance. A coefficient of variation (CV) was
308	also calculated. ²⁹ Bland-Altman plots were presented to assess systematic bias in the differences
309	in measurement of four parameters of Phase 2 (VO2peak, maximum RER, maximum HR,
310	maximum RPE). ³⁰ Formal tests of systematic bias were performed using linear regression to
311	examine whether the scatter in the Bland-Altman plots was heteroscedastic. ³¹ A mixed models
312	approach was used to examine the fixed effect of site and order of test (original vs. repeat).
313	Significance levels reported were 2-sided. Statistical analyses were performed using SAS
314	software, version 9.4 (SAS Institute, Inc, Cary, NC).
315	

316 **RESULTS**

317 Participant Characteristics

318 Of the 879 SOMMA participants, 875 performed CPET. Of the 4 who had no CPET

319 performed, 2 were never screened for CPET, one was not cleared for testing, and one was

320 cleared but was unable to use the treadmill. Of the 875 who attempted CPET, 84.8% were White;

321 59% were women; average age was 76.3 ± 5.0 years; and average BMI was 27.6 ± 4.6 kg/m².

322 The average 4-meter usual-pace gait speed was 1.04 ± 0.20 m/s. Only 41 (4.8%) had 3 or more

323 chronic conditions. Based on CHAMPS, participants reported an average baseline of 7 hours per

324 week of moderate-intensity physical activity (Table 2).

325	Of the 875 cleared for CPET, 19 (2.2%) were only cleared for the two sub-peak phases
326	(PWS, SWS). They were older, had slower average gait speed, more likely to have a history of
327	atrial fibrillation, were more likely to be a recurrent faller and had a higher prevalence of frailty
328	(p<0.05 for all, Table 2).

329

330 Comparison of Face Mask Type

Comparison of data from participants by mask type showed that the Hans Rudolph masks achieved greater consistency of ventilatory measures than the neoprene face mask. VO₂peak was similar for participants wearing either type of mask (p=0.29). However, participants wearing the Hans Rudolph mask were less likely to have their tests identified for adjudication (7.89% vs 17.02%, p<0.01). Of those participants with tests that needed adjudication, those wearing the Hans Rudolph mask were more likely to be adjudicated as valid (77.78% vs 25.00%, p<0.01). Few participants (n=6) had Phase 2 (Peak) stopped due to mask discomfort.

338

339 Completion of the 3 Phases of CPET

As shown in Figure 1, there was a high rate of completion for the CPET protocol; 863 (98.6%) completed Phase 1 (PWS) and 860 (98.3%) completed Phase 3 (SWS). A total of 852 (97.3%) performed Phase 2 (Peak). Older participants were less likely to finish Phase 1 or Phase 2, but had similar completion rates to younger participants for Phase 3 (Supplemental Table 1). Compared to non-frail participants, those classified as frail were more likely to not be cleared for Phase 2 (9.09% vs 1.60%). Recurrent fallers were also more likely not to be cleared for Phase 2 (5.41% vs 1.70%). Recurrent fallers who completed the CPET protocol, however, had similar

347	rates of risk alerts during the test as those who fell 0-1 times in the past year. Those "slow
348	walkers" were more likely to be unable to complete Phase 2 (Supplemental Table 2). Those with
349	3 or more comorbidities were more likely to not have performed Phase 2 and were more likely to
350	have stopped the protocol before reaching Phase 3. There were no differences in test completion
351	by obesity (Supplemental Table 3).

352

353 Pre-CPET Risk Alerts

Of the 876 screened for CPET eligibility, 189 (22%) had a low-risk alert during screening or CPET (Table 1). Blood pressure and ECG risk alerts during screening were common and were typically judged to be not serious such that the protocol was continued. Of the participants with a risk alert that occurred during screening, 94% were cleared for all 3 phases, and only 11% of those participants had an alert during CPET.

359

360 Safety During CPET

361 Very few participants had a risk alert during Phases 1 and 3 [PWS 5 (0.6%), SWS 2 (0.2%)]

362 (Table 1). Among 852 participants who attempted Phase 2 (Peak), 6% had a risk alert, although

363 most went on to complete Phase 3. The most common alert during testing was acute ischemia

pattern of ST-T changes (Phase 1, n=3; Phase 2, n=27; Phase 3, n=1). The medical safety officer

- 365 was notified of all high risk alerts or adverse events occurring during CPET (n=50 participants).
- 366 With the exception of 7 participants for whom the high risk alert was for a known condition, the
- 367 remaining 43 participants were either contacted in person (by phone, email, letter), or were
- 368 referred for medical treatment. There were two adverse events that occurred during Phase 2

369 (Peak). One participant fell on the treadmill. This adverse event resolved in one day with no need 370 for treatment, and was classified as mild severity with minor skin irritation and soft tissue 371 effects. One participant developed atrial fibrillation during the test and was referred to the 372 emergency room for treatment, resulting in an overnight hospitalization. This event was 373 considered serious, with resolution in one day. CPET for both these participants was stopped. 374 There were no statistically significant differences in the number of risk alerts during CPET 375 across age groups, frailty status, gait speed, multimorbidity status or obesity (Supplemental 376 Tables 1 -3).

377

378 Ventilatory Indices

Men had higher VO₂peak values on average than women (Table 3). The average maximum HR during Phase 2 (Peak) did not differ by sex. Men had a slightly higher maximum RER value during Phase 2 than women. (Figure 2). The average percentage of the maximum HR to the agepredicted maximum heart rate was 91.72 ± 11.42 , with 60% reaching 90% or more of their agepredicted maximum heart rate.

The average treadmill speed for Phase 1 (PWS) was 1.05 ± 0.18 m/s, with an average EC_w of 12.44 ± 2.49 mL/kg/min, and a cost-capacity ratio of 63.21% ± 12.39%. On average, men had higher PWS and EC_w, and lower cost-capacity ratio than women.

387 For Phase 3 (SWS) the average EC_W was 9.46 ± 1.64 mL/kg/min, and an average cost-

capacity ratio of 48.81 ± 12.56 . On average, men had higher EC_W and lower cost-capacity ratio than women.

390	For all but recurrent fallers, the average VO ₂ peak was significantly lower among those in the
391	compromised group (Supplemental Figure 1). Those 85 years and older had a lower average
392	VO2peak by 2.87 mL/kg/min compared to younger participants, those classified as frail had a
393	lower average VO2peak by 4.62 mL/kg/min compared to non-frail participants, those slow
394	walkers had a lower average VO_2 peak by 4.49 mL/kg/min compared to faster walkers, those with
395	\geq 3 comorbidities had a lower average VO ₂ peak by 3.23 mL/kg/min compared to those with 0-2
396	comorbidities, and obese participants had a lower average VO2peak by 3.50 mL/kg/min
397	compared to those with BMI<30 kg/m ² . VO ₂ peak declined with age (Figure 2).
• • • •	
398	
398 399	Adjudication Process
398 399 400	<i>Adjudication Process</i> Of the 852 participants that performed Phase 2 (Peak), 47 (5.5%) were flagged for
398399400401	<i>Adjudication Process</i> Of the 852 participants that performed Phase 2 (Peak), 47 (5.5%) were flagged for adjudication. (Figure 3) The majority (n=28) were due to low VO ₂ peak (VO ₂ <12 mL/kg/min),
 398 399 400 401 402 	Adjudication Process Of the 852 participants that performed Phase 2 (Peak), 47 (5.5%) were flagged for adjudication. (Figure 3) The majority (n=28) were due to low VO ₂ peak (VO ₂ <12 mL/kg/min), while 21 had low HR (maximum HR<100 bpm). Of the 47 adjudicated, data were deemed valid
 398 399 400 401 402 403 	Adjudication Process Of the 852 participants that performed Phase 2 (Peak), 47 (5.5%) were flagged for adjudication. (Figure 3) The majority (n=28) were due to low VO2peak (VO2 <12 mL/kg/min),
 398 399 400 401 402 403 404 	Adjudication Process Of the 852 participants that performed Phase 2 (Peak), 47 (5.5%) were flagged for adjudication. (Figure 3) The majority (n=28) were due to low VO2peak (VO2 <12 mL/kg/min), while 21 had low HR (maximum HR<100 bpm). Of the 47 adjudicated, data were deemed valid for 20 (42.6%). Nine (19.1%) were adjudicated as invalid because the participant was not able to complete the test. Eighteen (38.3%) were adjudicated as invalid, primarily due to technical or

406

407 *Repeatability*

The measurement of the Phase 2 (Peak) was highly reproducible (Table 4). The reliability as shown by the ICC demonstrated almost perfect agreement for VO₂peak (0.97), and substantial agreement for maximum HR, RER and RPE (0.74 - 0.86). The Bland-Altman plots for these measures (Figure 4) illustrate a random scattering of points above and below the average mean

412	difference with few points falling outside the 95% CI, showing a lack of systematic bias between
413	the first and second measurements. The formal tests of heteroscedasticity were not significant
414	(p>0.05). Results from mixed models for the Phase 2 measures did not show systematic bias
415	based on study site ($p > 0.07$) or whether the measurement was from the original or repeat
416	measurement ($p > 0.09$).
417	Likewise, the reliability of EC_W for Phases 1 and 3 (PWS, SWS) had strong agreement (ICCs
418	0.84, 0.78), but a poor agreement for RPE (ICCs 0.44, 0.19). Paired t-tests between the original
419	and repeat measures from these phases showed a significant difference for EC_W , RPE and cost-
420	capacity ratio, with the original measurements being higher on average than the repeat measures.
421	Results from mixed models did not show any systematic bias based on study site ($p > 0.09$), but
422	did show a systematic bias for whether the measurement was from the original or repeat
423	measurement for EC_W and cost-capacity ratio for both phases, and RPE for Phase 1 (p <0.05).

424

425 **DISCUSSION**

426 The primary finding from this study is that CPET was highly feasible and safe to effectively 427 obtain VO₂peak as the criterion measure of CRF among older community-dwelling adults, 428 including many with phenotypic features of frailty, multimorbidity, and poor physical function. 429 Of the 879 participants enrolled in SOMMA, 99.7% were deemed eligible for CPET, and of 430 those, 97.3% completed the peak exercise protocol. After adjudication, we obtained valid 431 VO₂peak values in 96.2% who attempted the test. Only 25 participants terminated CPET early. 432 While others have reported results from CPET in older adults, they have been from smaller studies or conglomerations of multiple studies ^{32–35}; and most lacked details regarding participant 433

434 selection, or excluded participants with poor physical function, frailty or multimorbidity.

435 Therefore, our study provides more generalizable data on the feasibility, safety and efficacy of

436 CPET across a wider range of older adults.

437 The utility of CPET for older adults has often been questioned, largely because of safety 438 concerns or reservations that many older adults cannot achieve peak exercise thresholds^{15,36} 439 and/or that they are unable to achieve sufficient motivation or stability to achieve high exercise 440 workloads. In SOMMA, we created a working group to design the CPET protocol specifically 441 for older adults. We implemented a familiarization protocol, protocol standardization, quality 442 control, safety alerts, and an adjudication process to assess valid VO₂peak tests. Because of these 443 rigorous methods, we obtained valid ventilatory measurements and had few risk alerts along with 444 a very high proportion of individuals who reliably achieved VO₂peak. This is particularly 445 important for multicenter, longitudinal studies.

446 One of the key findings is that CPET is feasible and safe in community-dwelling older adults 447 with a range of disease risk, disease burden and physical function when those with active 448 cardiopulmonary disease and very slow gait speed have been excluded. Although procedures 449 were implemented to exclude those in whom maximal exertion exercise was contraindicated, 450 only 1 participant was not cleared for any phase of CPET and 19 (2%) were not cleared for Phase 451 2 (Peak), with a remarkably high proportion of participants having completed Phase 2 without 452 incident. We monitored potential risk and uncovered a relatively small number of symptoms and 453 ECG abnormalities. There were only two adverse events, one considered mild severity.

There were no significant differences in the number of risk alerts during CPET across age
groups, frailty status, gait speed, multimorbidity status or obesity. Only 12.5% of alerts during
CPET were from previously known conditions. Notably, 29% of participants with risk indicators

during provocative exercise testing had a pre-CPET risk alert, suggesting high clinical value of
CPET, as well as predominant safety of the assessment. Our results confirm the utility of CPET
for ventilatory assessments in older adults, as well as for HR, BP, ECG, and other valuable
nonventilatory physiology.¹³

461 These SOMMA CPET data also provide an opportunity to evaluate additional metrics, 462 including submaximal respiratory data. The SOMMA cohort included participants at the lower 463 end of physical function in which CPET data are limited. The safety of CPET has been reported 464 previously, mostly in patients with cardiovascular and pulmonary disease³⁷, but also among generally healthy adults.³⁵ Still, less is known about the safety of CPET specifically in older 465 466 adults, especially those with compromised physical function. Participant selection criteria, the 467 diversity of populations studied and the CPET protocol all make it difficult to compare CPET 468 safety across studies, yet our study strengthens rationale and method for application of CPET in 469 older adults.

470 The average and range of VO₂peak values in SOMMA are consistent with other databases and smaller studies in older adults.^{33–35} The recently published Fitness Registry and the 471 472 Importance of Exercise: A National Data Base (FRIEND) showed VO₂peak ranged from 13.6-29.4 ml/kg/min in septuagenarian men and 12.3-22.8 ml/kg/min in septuagenarian women.³⁵ As 473 474 in SOMMA, CRF is lower in older versus younger adults, and lower in women versus men, and 475 there is heterogeneity among those being tested. SOMMA stands out in comparison to these 476 reports by clarifying the functional impact of multimorbidity, frailty, obesity and other factors 477 that are rarely assessed in CPET analyses. Future SOMMA analyses will explore in depth the 478 associations of CPET with these factors. Reliable measures of VO2peak will be crucial to 479 understand the mechanism underlying CRF and physical function. For example, we have

480	reported in SOMMA that VO ₂ peak is strongly associated with skeletal muscle mitochondrial
481	energetics. ³⁸ Longitudinal SOMMA data will be instrumental in determining a role for CRF in
482	mobility decline.

Repeated CPET showed excellent reproducibility for VO₂peak. These data are consistent with previous reports which showed similarly strong test-retest reproducibility.^{39,40} The low RPE ICC during PWS and SWS may be attributed to a familiarization bias. There were no systematic site differences for any of the measures across all phases, showing consistency between multiple operators at multiple sites. Given that SOMMA entails treadmill exercise, the reproducibility data are even more notable.

489

490 Limitations

491 Race and ethnic subgroups were not large enough to assess the differences of race/ethnicity.
492 Further, SOMMA excluded candidates who could not complete the 400-meter walk or who
493 walked <0.6 m/s over 4 meters, so results cannot be extended to those with more significant
494 mobility disability.

495

496 Conclusions

497 As a critical part of SOMMA we employed a CPET protocol that is feasible, safe, and 498 effective in older adults with a wide range of physical function and disease, and could be used 499 reliably as part of a multicenter study. SOMMA achieved high quality assessments of peak 500 performance as well as submaximal assessments of walking efficiency. CPET data will provide a

- 501 critical window into potential mechanisms underlying the biological aging process and risk for
- 502 functional decline and morbidity. Moreover, implications of the SOMMA CPET protocol imply
- 503 broader clinical and research potential, with generalizable efficacy for clinical care and research
- sold assessments among older adults. SOMMA uniquely demonstrates the value and utility of CPET,
- 505 with potential to better understand and moderate organ and cellular changes that are associated
- 506 with aging.

508 ARTICLE INFORMATION

509 Acknowledgements

- 510 CPET Working Group: Elvis A. Carnero; Steve Anthony; Cheyenne Barnett; Terri Blackwell;
- 511 Peggy Cawthon; Amelia Cervantes; Robin Collins; Michelle Danielson; Daniel Forman; Nancy
- 512 Glynn; Bret Goodpaster; Michelle Gordon; Teresa Harnish; Eileen Johnson; Justin Johnson ;
- 513 Kim Kennedy; Reagan Moffit; Anne Newman; Barbara Nicklas; Benjamin Schumacher;
- 514 Frederico G. S. Toledo; April Tuttle; Katey Webber; Cody Wolf.
- 515

516 Sources of Funding

- 517 The Study of Muscle, Mobility and Aging is supported by funding from the National Institute on
- 518 Aging, grant number AG059416." Study infrastructure support was funded in part by NIA
- 519 Claude D. Pepper Older American Independence Centers at University of Pittsburgh
- 520 (P30AG024827) and Wake Forest University (P30AG021332) and the Clinical and Translational
- 521 Science Institutes, funded by the National Center for Advancing Translational Science, at Wake
- 522 Forest University (UL1 0TR001420).

523 Disclosures

- 524 All authors report no conflicts.
- 525 Supplemental Material
- 526 **Tables S1-S3**

527 Figure S1

REFERENCES

530	1.	Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B,
531		Guazzi M, Gulati M, et al. Interdisciplinary Council on Quality of Care and Outcomes
532		Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific
533		statement from the American Heart Association. Circulation. 2010;122:191-225. doi:
534		10.1161/CIR.0b013e3181e52e69.
535		
536	2.	Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, Haskell WL,
537		Kaminsky LA, Levine BD, Lavie CJ, et al. Importance of Assessing Cardiorespiratory
538		Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific
539		Statement From the American Heart Association. Circulation. 2016;134:e653-e699. doi:
540		10.1161/CIR.00000000000461.
541		
542	3.	Ghosh S, Hota M, Chai X, Kiranya J, Ghosh P, He Z, Ruiz-Ramie JJ, Sarzynski MA,
543		Bouchard C. Exploring the underlying biology of intrinsic cardiorespiratory fitness
544		through integrative analysis of genomic variants and muscle gene expression profiling. J
545		Appl Physiol. (1985). 2019;126:1292-1314. doi: 10.1152/japplphysiol.00035.2018.
546		
547	4.	Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the
548		functional and prognostic evaluation of patients with pulmonary diseases. Respiration.
549		2009;771:3-17. doi: 10.1159/000186694.
550		

551	5.	Tran, D. (2018). Cardiopulmonary Exercise Testing. In P. C. Guest (Ed.), Investigations
552		of Early Nutrition Effects on Long-Term Health: Methods and Applications (pp. 285-
553		295). New York, NY: Springer New York.
554		
555	6.	Forman DE, Myers J, Lavie CJ, Guazzi M, Celli B, Arena R. Cardiopulmonary exercise
556		testing: relevant but underused. Postgrad Med. 2010;122:68-86. doi:
557		10.3810/pgm.2010.11.2225.
558		
559	7.	Decato TW, Bradley SM, Wilson EL, Hegewald MJ. Repeatability and Meaningful
560		Change of CPET Parameters in Healthy Subjects. Med Sci Sports Exerc. 2018;50:589-
561		595. doi: 10.1249/MSS.00000000001474.
562		
563	8.	Davies LC, Francis DP, Piepoli M, Scott AC, Ponikowski P, Coats AJ. Chronic heart
564		failure in the elderly: value of cardiopulmonary exercise testing in risk stratification.
565		Heart. 2000;832:147-51. doi: 10.1136/heart.83.2.147.
566		
567	9.	Mejhert M, Linder-Klingsell E, Edner M, Kahan T, Persson H. Ventilatory variables are
568		strong prognostic markers in elderly patients with heart failure. <i>Heart</i> . 2002;88:239-43.
569		doi: 10.1136/heart.88.3.239.
570		

10. Richardson CA, Glynn NW, Ferrucci LG, Mackey DC. Walking energetics, fatigability,
and fatigue in older adults: the study of energy and aging pilot. J Gerontol A Biol Sci Med
Sci. 2015;70:487-94. doi: 10.1093/gerona/glu146.
11. Schrack JA, Simonsick EM, Ferrucci L. The relationship of the energetic cost of slow
walking and peak energy expenditure to gait speed in mid-to-late life. Am J Phys Med
Rehabil. 2013;92:28-35. doi: 10.1097/PHM.0b013e3182644165.
12. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity
function in persons over the age of 70 years as a predictor of subsequent disability. N
Engl J Med. 1995;332:556-61. doi: 10.1056/NEJM199503023320902.
13. Forman DE, Arena R, Boxer R, Dolansky MA, Eng JJ, Fleg JL, Haykowsky M, Jahangir
A, Kaminsky LA, Kitzman DW, et al. Prioritizing Functional Capacity as a Principal End
Point for Therapies Oriented to Older Adults With Cardiovascular Disease: A Scientific
Statement for Healthcare Professionals From the American Heart Association.
Circulation. 2017;135:e894-e918. doi: 10.1161/CIR.000000000000483.
14. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB,
Houstis NE, Eisman AS, Hough SS, Lewis GD. Mechanisms of exercise intolerance in
heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen

592	extraction. Circ Heart Fail. 2015;8:286-94. doi:
593	10.1161/CIRCHEARTFAILURE.114.001825.
594	
595	15. Huggett DL, Connelly DM, Overend TJ. Maximal aerobic capacity testing of older
596	adults: a critical review. J Gerontol A Biol Sci Med Sci. 2005;60:57-66. doi:
597	10.1093/gerona/60.1.57.
598	
599	16. Church TS, Gill TM, Newman AB, Blair SN, Earnest CP, Pahor M. Maximal fitness
600	testing in sedentary elderly at substantial risk of disability: LIFE-P study experience. J
601	Aging Phys Act. 2008;16:408-15. doi: 10.1123/japa.16.4.408.
602	
603	17. Gill TM, DiPietro L, Krumholz HM. Role of exercise stress testing and safety monitoring
604	for older persons starting an exercise program. JAMA. 2000;284:342-9. doi:
605	10.1001/jama.284.3.342.
606	
607	18. Freemas JA, Wilhite DP, Greenshields JT, Adamic EM, Mickleborough TD. Comparison
608	between a facemask and mouthpiece on breathing mechanics and gas exchange variables
609	during high-intensity exercise. Eur J Sport Sci. 2020;20:211-218. doi:
610	10.1080/17461391.2019.1628309.
611	
612	19. Cummings SR, Newman AB, Coen PM, Hepple RT, Collins R, Kennedy K, Danielson
613	M, Peters K, Blackwell T, Johnson E, et al. The Study of Muscle, Mobility and Aging

(SOMMA). A Unique Cohort Study about the Cellular Biology of Aging and Age-related
Loss of Mobility. J Gerontol A Biol Sci Med Sci. 2023 Feb 9:glad052. doi:
10.1093/gerona/glad052. Epub ahead of print. PMID: 36754371.
20. Liguori Feito Y. Fountaine C. & Roy B. G. ACSM's guidelines for exercise testing and
prescription. American College of Sports Medicine. 2022;Eleventh edition.
21. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc.
1982;14:377-81.
22. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well
older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies
Depression Scale). Am J Prev Med. 1994;10:77-84.
23. Espeland MA, Crimmins EM, Grossardt BR, Crandall JP, Gelfond JA, Harris TB,
Kritchevsky SB, Manson JE, Robinson JG, Rocca WA, et al. Clinical Trials Targeting
Aging and Age-Related Multimorbidity. J Gerontol A Biol Sci Med Sci. 2017;72:355-
361. doi: 10.1093/gerona/glw220.
24. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy
R, Kop WJ, Burke G, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A
Biol Sci Med Sci. 2001;56:M146-56. doi: 10.1093/gerona/56.3.m146.

25. Fitti JE, Kovar MG. The Supplement on Aging to the 1984 National Health Interview

Survey. Vital Health Stat 1. 1987;(21):1-115.

6	3	6
•••	~	v

637

638

639	
640	26. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient
641	satisfaction in activities of daily living using a modified Stanford Health Assessment
642	Questionnaire. Arthritis Rheum. 1983;26:1346-53. doi: 10.1002/art.1780261107.
643	
644	27. Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL. CHAMPS physical
645	activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc.
646	2001;33:1126-41. doi: 10.1097/00005768-200107000-00010.
647	
648	28. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am
649	Coll Cardiol. 2001;37:153-6. doi: 10.1016/s0735-1097(00)01054-8.
650	
651	29. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol
652	Bull. 1979;86:420-8. doi: 10.1037//0033-2909.86.2.420.
653	
654	30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods
655	of clinical measurement. Lancet. 1986;1(8476):307-10.
656	

657	31. Hopkins WG. Measures of reliability in sports medicine and science. Sports Med.
658	2000;30:1-15. doi: 10.2165/00007256-200030010-00001.
659	
660	32. Scardovi AB, De Maria R, Celestini A, Perna S, Coletta C, Feola M, Aspromonte N,
661	Rosso GL, Carunchio A, Ferraironi A, et al. Additive prognostic value of
662	cardiopulmonary exercise testing in elderly patients with heart failure. Clin Sci (Lond).
663	2009;116:415-22. doi: 10.1042/CS20080111.
664	
665	33. Edvardsen E, Hansen BH, Holme IM, Dyrstad SM, Anderssen SA. Reference values for
666	cardiorespiratory response and fitness on the treadmill in a 20- to 85-year-old population.
667	Chest. 2013;144:241-248. doi: 10.1378/chest.12-1458.
668	
669	34. Loe H, Rognmo Ø, Saltin B, Wisløff U. Aerobic capacity reference data in 3816 healthy
670	men and women 20-90 years. PLoS One. 2013;8:e64319. doi:
671	10.1371/journal.pone.0064319. Erratum in: PLoS One. 2013;8(11).
672	doi:10.1371/annotation/e3115a8e-ca9d-4d33-87ef-f355f07db28e.
673	
674	35. Kaminsky LA, Arena R, Myers J, Peterman JE, Bonikowske AR, Harber MP, Medina
675	Inojosa JR, Lavie CJ, Squires RW. Updated Reference Standards for Cardiorespiratory
676	Fitness Measured with Cardiopulmonary Exercise Testing: Data from the Fitness
677	Registry and the Importance of Exercise National Database (FRIEND). Mayo Clin Proc.
678	2022;97:285-293. doi: 10.1016/j.mayocp.2021.08.020.

680	36. Kwok JM, Miller TD, Hodge DO, Gibbons RJ. Prognostic value of the Duke treadmill
681	score in the elderly. J Am Coll Cardiol. 2002;39:1475-81. doi: 10.1016/s0735-
682	1097(02)01769-2.
683	
684	37. Guazzi M, Bandera F, Ozemek C, Systrom D, Arena R. Cardiopulmonary Exercise
685	Testing: What Is its Value? J Am Coll Cardiol. 2017;70:1618-1636. doi:
686	10.1016/j.jacc.2017.08.012.
687	
688	38. Mau T, Lui LY, Distefano G, Kramer PA, Ramos SV, Toledo FGS, Santanasto AJ,
689	Shankland EG, Marcinek DJ, Jurczak MJ, et al. Mitochondrial energetics in skeletal
690	muscle are associated with leg power and cardiorespiratory fitness in the Study of
691	Muscle, Mobility, and Aging (SOMMA). J Gerontol A Biol Sci Med Sci. 2023;78:1367-
692	1375. doi: 10.1093/gerona/glac238.
693	
694	39. Marburger CT, Brubaker PH, Pollock WE, Morgan TM, Kitzman DW. Reproducibility
695	of cardiopulmonary exercise testing in elderly patients with congestive heart failure. Am J
696	Cardiol. 1998;82:905-9. doi: 10.1016/s0002-9149(98)00502-5.
697	
698	40. Barron A, Dhutia N, Mayet J, Hughes AD, Francis DP, Wensel R. Test-retest
699	repeatability of cardiopulmonary exercise test variables in patients with cardiac or

700 respiratory disease. *Eur J Prev Cardiol*. 2014;21:445-53. doi:

701 10.1177/2047487313518474.

703 Table 1. Risk Alerts occurring during CPET Eligibility or Testing: The Study of Muscle,

704 Mobility and Aging (SOMMA)

	Pre-CPET	Phase 1 (PWS)	Phase 2 (Peak)	Phase 3 (SWS)
Risk Alert Parameter	(N=876)	(N=875)	(N=852)	(N=863)
Alerts During Eligibility Screening:	149 (17.01)			
High Risk				
Electrocardiogram				
Atrial fibrillation/other supraventricular tachycardia with				
rate >100 (and no medical history)	1			
Substantial ventricular ectopy	0			
Acute infarct pattern	2			
Acute ischemia pattern of ST-T changes	0			
Acute pericarditis pattern	0			
2 nd degree (type 2) or 3 rd degree block	0			
QRS widening >120ms (no history of bundle branch block)	17			
Other acute abnormalities	2			
Blood Pressure				
Systolic >180 mmHg or <90 mmHg	1			
Diastolic >110 mmHg	0			
Heart Rate				
<40 bpm or >110 bpm	1			
Low Risk				
Electrocardiogram				
Pre-excitation	0			
1 st or 2 nd (type 1) degree heart block	56			
Other non-acute abnormalities	16			
Blood Pressure				
Systolic 160 to <180 or 90-100 mmHg	28			
Diastolic 100 to ≤ 110 mmHg	6			
Heart Rate	-			
90-110 bpm or 40-50 bpm	43			
Alerts During CPET:		5 (0.57)	51 (5.99)	2 (0.23)
High Risk		0 (0.07)		= (0.20)
Atrial fibrillation/other supraventricular tachycardia with				
rate >100 (and no medical history)		1	8	0
Substantial ventricular ectory		0	5	0 0
A cute ischemia nattern of ST-T changes		3	27	1
ORS widening >120ms (no history of bundle branch block)		0	1	0
Other acute abnormalities		1	5	0
Significant Pain		3	0	0
Other Alert		0	1	0
Adverse Event: Participant fall		0	1	0
L ow Dick		0	1	0
Other non coute charmalities		0	5	0
Systelia 160 to ≤ 180 or 00 100 mmHz		0	2	0
00.110 hmm or 40.50 hmm		U 1	С Л	0
Phase stormed certu?		1	4	1
rnase stopped early?		2	N T A	2
Completed		3	NA	2
Stopped early		2	NA 42	U
Participant went on to the next Phase		1	43	NA

- 705 Abbreviations: CPET, cardiopulmonary exercise testing; PWS, Preferred Walking Speed; SWS,
- 706 Slow Walking Speed. Data shown as n (%) or n.
- 707 Note: Data is on a participant level, so one participant may have multiple events.
- High risk alert: requiring review by the medical safety officer/study physician prior to participant
 leaving clinic or the same day as the clinic being notified of the finding;
- 710 Low risk alert: requiring review by the medical safety officer/study physician by at least the next
- 711 business day of observation or notification of the finding, with recommended follow-up with the
- 712 participant (if any) taken no more than 10 days after observation or notification of the finding, or
- 713 sooner if deemed medically necessary.
- 714

715 Table 2. Baseline Characteristics by CPET Eligibility: The Study of Muscle, Mobility and

716 Aging (SOMMA)

	All	All 3 Phases	Phase 1, 3 only	P-value*
Characteristic	(N= 875)	(N= 856)	(N=19)	
Site				< 0.001
University of Pittsburgh	437 (49.94)	435 (50.82)	2 (10.53)	
Wake Forest University School of Medicine	438 (50.06)	421 (49.18)	17 (89.47)	
Age (years)	76.34 ± 4.99	76.28 ± 4.96	79.11 ± 5.74	0.01
Sex				
Women	517 (59.09)	505 (59.00)	12 (63.16)	0.72
Men	358 (40.91)	351 (41.00)	7 (36.84)	
Race		~ /		0.59
Black	115 (13.14)	113 (13.20)	2 (10.53)	
White	742 (84.80)	726 (84.81)	16 (84.21)	
Other race	18 (2.06)	17 (1.99)	1 (5.26)	
Smoking status		~ /		0.48
Never	490 (56.32)	477 (56.05)	13 (68.42)	
Past	355 (40.80)	349 (41.01)	6 (31.58)	
Current	25 (2.87)	25 (2.94)	0	
Beta blocker use with 30 days of baseline	163 (18.67)	156 (18.27)	7 (36.84)	0.07
CHAMPS: Hours/week in moderate-intensity exercise-				,
related activities (MET≥3)	7.03 ± 7.09	7.06 ± 7.12	5.57 ± 5.08	0.48
Body mass index (kg/m ²)	27.60 ± 4.56	27.58 ± 4.56	28.22 ± 4.69	0.55
Body mass index $\geq 30 \text{ kg/m}^2$	250 (28.57)	243 (28.39)	7 (36.84)	0.42
4-meter walk gait speed (m/s)	1.04 ± 0.20	1.04 ± 0.20	0.88 ± 0.12	< 0.001
4-meter walk gait speed ≤ 0.8 m/s	89 (10.17)	84 (9.81)	5 (26.32)	0.04
SOMMA Multimorbidity Index (0-11)	``			
0	371 (42.99)	364 (43.13)	7 (36.84)	0.07
1	340 (39.40)	335 (39.69)	5 (26.32)	
2	111 (12.86)	107 (12.68)	4 (21.05)	
3+	41 (4.75)	38 (4.50)	3 (15.79)	
History of:				
Cancer, excluding non-melanoma skin cancer	217 (24.89)	210 (24.62)	7 (36.84)	0.28
Cardiac arrhythmia (atrial fibrillation)	34 (3.90)	31 (3.63)	3 (15.79)	0.03
Chronic kidney disease or renal failure	33 (3.79)	33 (3.87)	0	1.00
Chronic obstructive pulmonary disease/other lung disease	115 (13.19)	111 (13.01)	4 (21.05)	0.30
Coronary heart disease	59 (6.77)	56 (6.57)	3 (15.79)	0.13
Congestive heart failure	6 (0.69)	6 (0.70)	0	1.00
Depression (CES-D-10>10)	73 (8.45)	71 (8.40)	2 (10.53)	0.67
Diabetes mellitus	131 (15.02)	128 (15.01)	3 (15.79)	1.00
Stroke	21 (2.41)	20 (2.34)	1 (5.26)	0.37
Aortic stenosis	8 (0.92)	7 (0.82)	1 (5.26)	0.16
Age-Predicted Maximal Heart Rate (bpm)	154.56 ± 3.49	154.60 ± 3.47	152.63 ± 4.02	0.01
Recurrent faller (2+ in past year)	111(12.73)	105(12.31)	6 (31.58)	0.03
Any difficulty walking 2-3 blocks	33 (3.81)	31 (3.65)	2(1111)	0.15
Frailty status	22 (0.01)	01 (0100)	- ()	0.10
Robust	386 (44 11)	382 (44 63)	4 (21.05)	< 0.001
Intermediate (pre-frail)	423 (48 34)	414 (48 36)	9 (47.37)	0.001
Frail	66 (7.54)	60 (7.01)	6 (31.58)	

- 717 Abbreviations: CES-D, Center for Epidemiological Studies-Depression; CHAMPS, Community Healthy
- 718 Activities Model Program for Seniors; CPET, cardiopulmonary exercise testing; MET, metabolic
- 719 equivalent of task; SOMMA, Study of Muscle, Mobility and Aging.
- 720 Data shown as mean \pm SD or n(%)
- *P-values from a t-test for normally distributed continuous variables, a Wilcoxon rank-sum test for
- skewed continuous data, a chi-square test for categorical data or a Fisher's exact test for categorical data
- 723 with low expected cell counts.

725	Tables 3.	CPET	measures by se	x: The Stud	v of Muscle.	Mobility	and Aging	(SOMMA)
	-		2		,	, J	00	()

CPET Measure	All	Men	Women	P-value*
	(N= 875)	(N=358)	(N= 517)	
Phase 1: Preferred Walking Speed				
Energetic cost of walking (mL/kg/min)	12.44 ± 2.49	12.95 ± 2.47	12.07 ± 2.44	<.0001
Rating of Perceived Exertion (6-20)	10.50 ± 2.03	10.32 ± 2.03	10.64 ± 2.02	0.02
Heart rate (bpm)	103.74 ± 17.22	99.35 ± 16.48	106.82 ± 17.08	<.0001
Respiratory exchange ratio	0.90 ± 0.09	0.90 ± 0.09	0.89 ± 0.09	0.11
Treadmill speed (m/s)	1.05 ± 0.18	1.08 ± 0.17	1.02 ± 0.18	<.0001
Cost-Capacity Ratio (%)	63.21 ± 12.39	59.90 ± 12.96	65.61 ± 11.39	<.0001
Phase 2: Peak				
VO ₂ peak (mL/kg/min)	$\begin{array}{c} 20.22 \pm 4.82 \\ 1528.30 \ \pm \end{array}$	$\begin{array}{c} 22.27 \pm 5.00 \\ 1865.62 \ \pm \end{array}$	$\begin{array}{c} 18.75 \pm 4.11 \\ 1286.95 \pm \end{array}$	<.0001
VO ₂ peak (mL/min)	433.40	410.69	248.94	<.0001
Maximum Rating of Perceived Exertion (6-20)	17.65 ± 1.42	17.66 ± 1.37	17.64 ± 1.46	0.91
Maximum heart rate (bpm)	141.87 ± 18.00	140.50 ± 18.24	142.82 ± 17.79	0.07
Maximum heart rate as a percentage of APMHR	91.72 ± 11.42	90.85 ± 11.59	92.33 ± 11.27	0.06
Respiratory exchange ratio at peak	1.13 ± 0.09	1.13 ± 0.09	1.12 ± 0.09	0.02
Maximum Respiratory exchange ratio	1.14 ± 0.09	1.15 ± 0.08	1.14 ± 0.09	0.04
Phase 3: Slow Walking Speed (1.5 mph)				
Energetic cost of walking (mL/kg/min)	9.46 ± 1.64	9.61 ± 1.59	9.35 ± 1.66	0.02
Rating of Perceived Exertion (6-20)	8.41 ± 1.90	8.18 ± 1.70	8.57 ± 2.01	0.008
Heart rate (bpm)	100.08 ± 15.78	96.73 ± 15.41	102.40 ± 15.63	<.0001
Respiratory exchange ratio	0.80 ± 0.06	0.80 ± 0.06	0.80 ± 0.07	0.13
Cost-Capacity Ratio (%)	48.81 ± 12.56	44.90 ± 11.22	51.61 ± 12.73	<.0001

726 Abbreviations: APMHR, Age-Predicted Maximal Heart Rate; CPET, cardiopulmonary exercise

testing; PWS, Preferred Walking Speed; SWS, Slow Walking Speed; VO₂, oxygen consumption;

728 VO₂peak, peak oxygen consumption.

729 Data shown as mean \pm SD or n(%)

730 *P-values from a t-test for normally distributed continuous variables, a Wilcoxon rank-sum test

731 for skewed continuous data.

Table 4. CPET repeatability (n=30): The Study of Muscle, Mobility and Aging (SOMMA)

					Pearson		
			Difference*	Absolute	Correlation	CV	ICC
CPET Measure	Original	Repeat	(Original - Repeat)	Difference	(95% CI)**		(95% CI)
Phase 1: Preferred Walking Speed							
Energetic cost of walking (mL/kg/min)	12.55 ± 2.69	11.90 ± 2.62	$0.64 \pm 1.37*$	1.01 ± 1.11	0.87 (0.74, 0.94)	11.17	0.84 (0.92, 0.70)
Rating of Perceived Exertion (6-20)	10.13 ± 2.03	9.21 ± 2.02	$0.93\pm2.00\texttt{*}$	1.69 ± 1.39	0.52 (0.19, 0.75)	20.65	0.44 (0.69, 0.11)
Heart rate (bpm)	103.27 ± 13.76	102.63 ± 13.27	0.63 ± 8.51	6.70 ± 5.13	0.80 (0.62,0.90)	8.26	0.81 (0.90,0.64)
Respiratory exchange ratio	0.90 ± 0.09	0.90 ± 0.06	0.00 ± 0.05	0.04 ± 0.03	0.78 (0.58,0.89)	6.12	0.75 (0.87,0.54)
Cost-capacity ratio (%)	61.68 ± 13.23	59.55 ± 12.80	$2.13\pm5.25\texttt{*}$	4.32 ± 3.60	0.92 (0.84, 0.96)	8.66	0.91 (0.96, 0.82)
Phase 2: Peak							
VO ₂ peak (mL/kg/min)	21.06 ± 5.87	20.66 ± 5.55	0.40 ± 1.39	1.12 ± 0.90	0.97 (0.94, 0.99)	6.68	0.97 (0.98, 0.94)
VO ₂ peak (mL/min)	1580.70 ± 439.64	1546.50 ± 400.52	34.20 ± 109.33	85.47 ± 74.88	0.97 (0.94, 0.99)	6.99	0.96 (0.98, 0.93)
Maximum Rating of Perceived Exertion (6-20)	17.80 ± 1.42	17.73 ± 1.17	0.07 ± 0.94	0.67 ± 0.66	0.75 (0.54, 0.88)	5.32	0.74 (0.87, 0.53)
Maximum heart rate (bpm)	144.00 ± 18.65	141.90 ± 17.32	2.10 ± 9.30	7.83 ± 5.26	0.87 (0.74, 0.94)	6.51	0.86 (0.93, 0.74)
Maximum Respiratory exchange ratio	1.15 ± 0.09	1.14 ± 0.07	0.00 ± 0.06	0.04 ± 0.04	0.77 (0.57, 0.89)	4.96	0.76 (0.88, 0.56)
VCO ₂ (mL/min) at peak	1799.83 ± 519.13	1741.63 ± 445.89	58.20 ± 159.88	122.87 ± 115.97	0.96 (0.91, 0.98)	9.03	0.94 (0.97, 0.88)
VE/VO ₂ ratio at peak	39.87 ± 7.46	38.90 ± 5.56	0.97 ± 4.54	3.17 ± 3.34	0.80 (0.61, 0.90)	11.52	0.76 (0.88, 0.56)
End-tidal carbon dioxide (mmHg) at peak	34.53 ± 4.76	34.43 ± 4.48	0.10 ± 2.17	1.43 ± 1.61	0.89 (0.78, 0.95)	6.30	0.89 (0.95, 0.79)
Phase 3: Slow Walking Speed (1.5 mph)							
Energetic cost of walking (mL/kg/min)	9.68 ± 1.71	9.14 ± 1.51	$0.54\pm0.94\texttt{*}$	0.80 ± 0.73	0.84 (0.68, 0.92)	10.02	0.78 (0.89, 0.60)
Rating of Perceived Exertion (6-20)	8.33 ± 1.75	8.17 ± 1.69	$0.21\pm2.21\texttt{*}$	1.52 ± 1.60	0.18 (-0.20, 0.51)	26.77	0.19 (0.51, -0.18)
Heart rate (bpm)	102.00 ± 12.79	100.07 ± 9.99	1.93 ± 8.02	6.53 ± 4.90	0.78 (0.58,0.89)	7.93	0.75 (0.87,0.54)
Respiratory exchange ratio	0.80 ± 0.06	0.80 ± 0.06	0.00 ± 0.06	0.04 ± 0.03	0.60 (0.30,0.79)	6.96	0.60 (0.79,0.32)
Cost-capacity ratio (%)	48.58 ± 12.95	46.58 ± 11.72	$2.00\pm4.16\texttt{*}$	3.40 ± 3.08	0.95 (0.89, 0.98)	8.74	0.93 (0.97, 0.86)

Abbreviations: CPET, cardiopulmonary exercise testing; CI, confidence interval; CV, coefficient of variation; ICC, intraclass correlation coefficient; VCO₂, carbon dioxide exhalation; VE, minute ventilation; VO₂, oxygen inhalation; VO₂peak, peak oxygen inhalation. *paired t-tests (original and repeat) p<0.05.

**All p-values <0.01.





Abbreviations: CPET, cardiopulmonary exercise testing; ppt, participant; PWS, Preferred Walking Speed; SOMMA, Study of Muscle, Mobility and Aging.

Figure 2: Distributions of CPET measures from Phase 2 (Peak) by Sex: The Study of Muscle, Mobility and Aging (SOMMA)



Abbreviations: APMHR, Age-Predicted Maximal Heart Rate; CPET, cardiopulmonary exercise testing; RER, respiratory exchange ratio; RPE, rating of perceived exertion; VO₂peak, peak oxygen consumption.





*Gas exchange was measured with a Medgraphics (N=12) or a Hans Rudolph (N=6) mask Abbreviations: CPET, cardiopulmonary exercise testing; RER, respiratory exchange ratio; RPE, rating of perceived exertion; SOMMA, Study of Muscle, Mobility and Aging; VO₂peak, peak oxygen utilization.

Figure 4. Bland-Altman plots showing the agreement between the original and repeat CPETs: The Study of Muscle, Mobility and Aging (SOMMA)

A. VO₂peak (mL/kg/min)

B. Maximum RER



Abbreviations: CPET, cardiopulmonary exercise testing; RER: respiratory exchange ratio; RPE: rating of perceived exertion; VO₂peak, peak oxygen consumption. Dotted lines represent upper and lower 95% limits of agreement. The unbroken red line represents mean differences.